J&J says new data confirms long-term survival benefit of Impella CP heart pump

Johnson & Johnson (NYSE:JNJ) announced groundbreaking long-term data from the DanGer Shock randomized controlled trial for its Impella CP heart pump, published in The New England Journal of Medicine and presented at the European Society of Cardiology Congress.


The study demonstrated that Impella CP achieved an absolute mortality reduction of 16.3% over 10 years compared to standard care, with patients gaining an average of 600 additional days of life. This improvement surpasses the initial 6-month data, which showed a 12.7% reduction in mortality.

The trial, which enrolled 360 participants across 14 sites in Denmark, Germany, and the UK, led to the American College of Cardiology and American Heart Association upgrading Impella to a class 2a guideline recommendation. This marks Impella CP as the first mechanical circulatory support device proven to provide both short-term and long-term survival benefits in STEMI-related cardiogenic shock patients.

https://www.stocktitan.net/news/JNJ/new-data-from-the-dan-ger-shock-randomized-control-trial-published-mdbfdx0plz1r.html